Form 4 for STLN Starling Oncology, Inc.
Accepted 2026-05-22 17:32:19 ET · period of report 2026-05-21 · accession 0001079973-26-000723 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-22 17:32 | 2026-05-21 | STLN | Carter Robert Ross | CFO | J - Other | $4.47 | -1,604 | 414.8K | -0.4% | -$7,170 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-21 | J | D | 1,604 | $4.47 | 414,801 | D | — | — | (F1) The Issuer executed the sale to cover the tax liabilities arising from the vesting of an RSU award made on May 21, 2024. |